Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

在非小细胞肺癌中，KRAS基因突变的比例不是特别高，其中KRAS基因G12C突变在白种人突变的概率是10%，在亚裔患者的突变概率是3%。经过数十年的研究，针对KRAS基因G12C目前已经有了靶向药，Sotorasib（中文翻译为：索托拉西布）是一种口服靶向药。在相应的三期临床试验中，相比化疗药多西他赛，索托拉西布显著延长了患者的中位 ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

The research, led by CCU Department of Physiology Chair Professor Tsai Shaw-jenq and NCKU College of Medicine Dean Shan ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...